|
業務類別
|
Biotechnology |
|
業務概覽
|
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). |
| 公司地址
| One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129 |
| 電話號碼
| +1 415 707-6312 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.braveheart.bio |
| 員工數量
| 30 |
| Mr. J. Paul Rickey |
Chief Financial Officer and Principal Accounting Officer |
美元 73.33K |
15/07/2026 |
| Dr. Travis Murdoch, M.D. |
Director, President and Chief Executive Officer |
美元 160.99K |
15/07/2026 |
| Ms. Michele Anderson |
Chief Development Officer |
美元 102.61K |
15/07/2026 |
| Dr. Tyler Chavez, PhD |
Chief Business Officer |
-- |
15/07/2026 |
| Mr. Marc Evanchik |
Chief Scientific Officer |
-- |
15/07/2026 |
| Dr. Emil deGoma, M.D. |
Chief Medical Officer |
-- |
15/07/2026 |
|
|
| Mr. Christopher A. Viehbacher |
Chairman of the Board |
15/07/2026 |
| Mr. David Malek |
Director |
15/07/2026 |
| Mr. David Charles Lubner, C.P.A.,M.S. |
Independent Director |
15/07/2026 |
| Dr. Jason V. Coloma, PhD |
Director |
15/07/2026 |
| Mr. Erez Chimovits, M.B.A.,M.Sc. |
Independent Director |
15/07/2026 |
| Dr. Travis Murdoch, M.D. |
Director, President and Chief Executive Officer |
15/07/2026 |
| Dr. Jasper Bos, PhD |
Independent Director |
15/07/2026 |
| Dr. Vineeta Agarwala, M.D.,PhD |
Independent Director |
15/07/2026 |
| Dr. Tim Lohoff, PhD |
Independent Director |
15/07/2026 |
|
|
|
|
